Search
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization du...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsNaringin
go.drugbank.com/drugs/DB16859ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigationalPatients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalImlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigationalBenzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHydrastine
go.drugbank.com/drugs/DB19354ExperimentalCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 SubstratesEquilenin
go.drugbank.com/drugs/DB03515ExperimentalEquilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates